

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A chimeric polypeptide, said chimeric polypeptide comprising:
 - a) a first domain comprising ~~extracellular or an~~ intracellular portions of a G protein coupled receptor, and
 - b) at least a second domain, attached to the first domain, wherein said second domain is ~~a~~ naturally or non-naturally occurring hydrophobic ~~moiety~~ moieties,
wherein said first domain does not comprise a native extracellular ligand portion of said GPCR.
2. (Original) The chimeric polypeptide of claim 1, wherein said second or more domains are attached at either one end, at both ends, or at an internal position of said first domain.
3. (Currently amended) The chimeric polypeptide of claim 1, wherein said hydrophobic moiety is ~~selected from the group consisting of: a lipid, an acetyl or an amino acid.~~
4. (Currently amended) The chimeric polypeptide of claim 3, wherein said hydrophobic moiety is selected from the group consisting of: ~~stearoyl (C18), palmitoylate (C16), myristoyl (C124), lauryl (C12), capryl (C10), and capryloyl (C68), phospholipids, steroids, sphingosines, ceramides, octyl-glycine, 2-cyclohexylalanine, or benzoylphenylalanine,~~ wherein said hydrophobic moiety is attached to said chimeric polypeptide with amide bonds, sulphydryls, amines, alcohols, phenolic groups, or carbon-carbon bonds.
5. Cancelled.
6. (Original) The chimeric polypeptide of claim 1, wherein said intracellular portion is selected from the group consisting of: the first intracellular loop or a fragment thereof, the second intracellular loop or a fragment thereof, the third intracellular loop or a fragment thereof, and the fourth intracellular domain or a fragment thereof, of said G-protein coupled receptor.
- 7.- 9. Cancelled.

Applicants: Kuliopoulos *et al.*
U.S.S.N. 09/841,091

10. (Original) The chimeric polypeptide of claim 6, where said intracellular portion is at least 3 contiguous amino acid residues.
11. (Original) The chimeric polypeptide of claim 6, wherein said intracellular portion is at least 5 contiguous amino acid residues.
12. (Original) The chimeric polypeptide of claim 6, wherein said intracellular portion comprises the third intracellular loop of the GPCR.
13. (Original) The chimeric polypeptide of claim 12, wherein said intracellular portion comprises at least 7 contiguous amino acid residues of the third intracellular loop.
14. (Currently amended) The chimeric polypeptide of claim 1, wherein said first domain comprises a PAR and said second domain comprises a lipid moiety GPCR transmembrane domain or a fragment thereof.
15. Cancelled.
16. Cancelled.
17. Cancelled.
18. Cancelled.
19. (Currently amended) The chimeric polypeptide of claim 18, wherein the G-protein coupled receptor or fragment thereof, is selected from the group consisting of a luteinizing hormone receptor, a follicle stimulating hormone receptor, a thyroid stimulating hormone receptor, a calcitonin receptor, a glucagon receptor, a glucagon-like peptide 1 receptor (GLP-1), a metabotropic glutamate receptor, a parathyroid hormone receptor, a vasoactive intestinal peptide receptor, a secretin receptor, a growth hormone releasing factor (GRF) receptor, protease-activated receptors (PARs), cholecystokinin receptors, somatostatin receptors, melanocortin receptors, ADP receptors, adenosine receptors, thromboxane receptors, platelet activating factor receptor, adrenergic receptors, 5-HT receptors, CXCR4, CCR5, chemokine receptors, neuropeptide receptors, opioid receptors, erythropoietin receptor, von Willebrand receptor, parathyroid hormone (PTH) receptor, vasoactive intestinal peptide (VIP) receptor, and collagen receptors.
20. – 28. Cancelled.
29. (Original) A pharmaceutical composition comprising the chimeric polypeptide of claim 1 and a pharmaceutically acceptable carrier.

Applicants: Kuliopoulos *et al.*
U.S.S.N. 09/841,091

30. Cancelled.

31. (Original) A kit comprising in one or more containers, the pharmaceutical composition of claim 29.

32.- 34. Cancelled.

--35. (New) The chimeric polypeptide of claim 1, wherein said G-protein coupled receptor is a mammalian G-protein coupled receptor.

36. (New) The chimeric polypeptide of claim 4, wherein said hydrophobic moiety is palmitoyl.

37. (New) The chimeric polypeptide of claim 19, wherein said G-protein coupled receptor is a protease-activated receptor (PAR).

38. (New) The chimeric polypeptide of claim 37, wherein the protease-activated receptor is selected from the group consisting of PAR1, PAR2, and PAR4.

39. (New) The chimeric polypeptide of claim 12, wherein said intracellular portion comprises a sequence selected from the group consisting of SEQ ID NO: 1-16, 19-23, and 29.

40. (New) The chimeric polypeptide of claim 12, wherein said intracellular portion comprises a sequence selected from the group consisting of SEQ ID NO: 1-10, and 23.

41. (New) The chimeric polypeptide of claim 1, wherein the said G-protein coupled receptor is selected from the group consisting of CCKA, CCKB, SSTR2, and SubP receptors.

42. (New) The chimeric polypeptide of claim 3, wherein said hydrophobic moiety is a steroid.

43. (New) A chimeric polypeptide, said chimeric polypeptide comprising:

- a) a first domain comprising an intracellular portion of a protease-activated receptor (PAR), and
- b) a second domain, attached to the first domain, wherein said second domain is palmitate.--